|Table of Contents|

Risk factors analysis and nomogram prediction model construction of postoperative cardiopulmonary complications in thoracoscopic lung cancer resection

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 04
Page:
663-667
Research Field:
Publishing date:

Info

Title:
Risk factors analysis and nomogram prediction model construction of postoperative cardiopulmonary complications in thoracoscopic lung cancer resection
Author(s):
PAN Yongdong1; ZHU Ping1; LYU Wei2
1.Yichun People's Hospital,Jiangxi Yichun 336000,China;2.Jiangxi University of Traditional Chinese Medicine Hospital,Jiangxi Nanchang 333000,China.
Keywords:
lung cancer; thoracoscopic resection; cardiopulmonary complications; risk factors; nomogram prediction model
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.04.013
Abstract:
Objective:To explore the risk factors of cardiopulmonary complications in lung cancer patients underwent thoracoscopic resection and construct a nomogram prediction model.Methods:228 lung cancer patients who underwent thoracoscopic resection in our hospital from October 2019 to September 2022 were selected as the study subjects.52 patients with postoperative cardiopulmonary complications were included in the occurrence group,and 176 patients without cardiopulmonary complications were included in the non-occurrence group.Record clinical data of two groups of patients.Univariate analysis was performed by independent sample t-test or χ2,to explore the related factors of cardiopulmonary complications after thoracoscopic resection.MedCalc software performed ROC curve analysis on measurement indicators to explore its predictive value for cardiopulmonary complications after thoracoscopic resection.Logistic stepwise regression analysis explored independent risk factors for cardiopulmonary complications after thoracoscopic resection.The R language software 4.0 "rms" package constructed a nomogram prediction model for lung cancer patients with cardiopulmonary complications after thoracoscopic resection.The calibration curve was used to internally validate the nomogram prediction model,and the concordance index (C-index) was calculated.The decision curve was used to evaluate the clinical predictive efficacy of the nomogram prediction model.Results:There were significant differences in age,smoking history,diabetes history,coronary heart disease history,operation time,intraoperative blood loss and FEV1 between the occurrence group and the non-occurrence group.The AUC for age,surgical time,and intraoperative bleeding was 0.739,0.785,and 0.736,respectively,with the optimal cutoff values of 55 years old,178 minutes,and 96 mL,respectively.Age,smoking history,history of coronary heart disease,surgical time,and FEV1 were independent risk factors for cardiopulmonary complications in lung cancer patients underwent thoracoscopic resection.The internal validation results indicated that the calibration curve of the nomogram prediction model was close to the original and ideal curves,with a C-index of 0.883 (95%CI:0.833~0.933),indicating a high degree of model fit.The nomogram prediction model had a threshold of>0.23,which can provide clinical net benefits,and the clinical net benefits were all higher than age,smoking history,coronary heart disease history,surgical time,and FEV1.Conclusion:This study constructed nomogram prediction model based on the independent risk factors of cardiopulmonary complications after thoracoscopic lung cancer resection,namely age,smoking history,coronary heart disease history,operation time,and FEV1,which has a good predictive value for the occurrence of cardiopulmonary complications,and is helpful for clinical monitoring of cardiopulmonary complications in patients with thoracoscopic lung cancer resection,in order to reduce the incidence rate of cardiopulmonary complications and reduce the incidence of adverse events.

References:

[1]RUIZ-CORDERO R,DEVINE WP.Targeted therapy and checkpoint immunotherapy in lung cancer［J］.Surg Pathol Clin,2020,13(1):17-33.
[2]OLIVER AL.Lung cancer:epidemiology and screening［J］.Surg Clin North Am,2022,102(3):335-344.
[3]WU F,WANG L,ZHOU C.Lung cancer in China:current and prospect［J］.Curr Opin Oncol,2021,33(1):40-46.
[4]BADE BC,DELA CRUZ CS.Lung cancer 2020:Epidemiology,etiology,and prevention［J］.Clin Chest Med,2020,41(1):1-24.
[5]TOMOYASU M,DEGUCHI H,KUDO S,et al.Evaluation of pulmonary artery bleeding during thoracoscopic pulmonary resection for lung cancer［J］.Thorac Cancer,2022,13(21):3001-3006.
[6]FIDLER MJ,FHIED CL,RODER J,et al.The serum-based VeriStrat test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients［J］.BMC Cancer,2018,18(1):310.
[7]孙梦寒,茆梦,孙杰.胸腔镜部分肺切除术后肺部并发症的危险因素［J］.临床麻醉学杂志,2020,36(08):759-762. SUN MH,MAO M,SUN J.Risk factors for pulmonary complications after thoracoscopic partial pneumonectomy［J］.Journal of Clinical Anesthesiology,2020,36(08):759-762.
[8]MAZZUCCHI E.Both the nomogram and the score system can represent an useful tool especially in those cases where the complication is foreseen by the surgeon［J］.Int Braz J Urol,2022,48(5):828-829.
[9]陈孝平,汪建平.外科学［M］.第8版.北京:人民卫生出版社,2013:282. CHEN XP,WANG JP.Surgery［M］.8th ed.Beijing:People's Health Press,2013:282.
[10]乔景艳,王芳,唐华平.肺癌合并肺栓塞41例患者临床特点分析［J］.中国临床医生杂志,2023,51(01):47-49. QIAO JY,WANG F,TANG HP.Analysis of clinical characteristics of 41 patients with lung cancer combined with pulmonary embolism［J］.Chinese Journal of Clinical Physicians,2023,51(01):47-49.
[11]中华医学会,中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2018版)［J］.肿瘤研究与临床,2018,30(12):793-824. Chinese Medical Association,Chinese Medical Association Oncology Branch,Journal of Chinese Medical Association.Clinical diagnosis and treatment guideline of lung cancer of Chinese Medical Association(2018 edition)［J］.Oncology Research and Clinics,2018,30(12):793-824.
[12] 纪素清.吉西他滨加顺铂联合治疗晚期肺癌8例临床报告［J］.中国现代药物应用,2011,5(17):86. JI SQ.Combination of gemcitabine and cisplatin in the treatment of advanced lung cancer: a report of 8 cases［J］.Chinese Journal of Modern Drug Application,2011,5(17):86.
[13]田田,魏东华,徐叶红,等.2015-2019年合肥市城市居民肺癌筛查结果分析［J］.中华肿瘤防治杂志,2022,29(23):1653-1658. TIAN T,WEI DH,XU YH,et al.Analysis of lung cancer screening results among urban residents in Hefei City from 2015 to 2019［J］.Chinese Journal of Tumor Prevention and Control,2022,29(23):1653-1658.
[14]罗汶鑫,杨澜,王成弟,等.肺癌筛查与早期诊断的研究现状与挑战［J］.中国科学:生命科学,2022,52(11):1603-1611. LUO WX,YANG L,WANG CD,et al.Research status and challenges of lung cancer screening and early diagnosis［J］.Chinese Science:Life Sciences,2022,52(11):1603-1611.
[15]IASONOS A,SCHRAG D,RAJ GV,et al.How to build and interpret a nomogram for cancer prognosis［J］.J Clin Oncol,2008,26(8):1364-1370.
[16]何春明,尹航,唐健,等.基于SEER数据库的老年肺癌术后患者预后模型构建与内部验证［J］.上海交通大学学报(医学版),2020,40(11):1554-1561. HE CM,YIN H,TANG J,et al.Construction and internal validation of a prognostic model for elderly postoperative lung cancer patients based on SEER database［J］.Journal of Shanghai Jiao Tong University (Medical Edition),2020,40(11):1554-1561.
[17]李震宇,张磊冰,王俊,等.胸腔镜治疗老年早期肺癌围术期心肺并发症危险因素分析［J］.重庆医学,2016,45(22):3055-3056,3059. LI ZY,ZHANG LB,WANG J,et al.Analysis of risk factors for perioperative cardiopulmonary complications in thoracoscopic treatment of early stage lung cancer in the elderly［J］.Chongqing Medicine,2016,45(22):3055-3056,3059.
[18]王元达.肺癌患者胸腔镜术后发生心肺并发症的相关影响因素分析［J］.实用癌症杂志,2023,38(01):172-174. WANG Yuanda.Analysis of influential factors related to the occurrence of cardiopulmonary complications after thoracoscopic surgery in lung cancer patients［J］.Journal of Practical Cancer,2023,38(01):172-174.
[19]LI Y,MA YL,GAO YY,et al.Analysis of the risk factors of postoperative cardiopulmonary complications and ability to predicate the risk in patients after lung cancer surgery［J］.J Thorac Dis,2017,9(6):1565-1573.
[20]王新,王炯杰,王雷,等.肺癌患者胸腔镜术后心肺并发症预测模型的建立与分析［J］.现代肿瘤医学,2022,30(13):2351-2356. WANG X,WANG JJ,WANG L,et al.Establishment and analysis of prediction model for cardiopulmonary complications after thoracoscopic surgery in lung cancer patients［J］.Modern Oncology,2022,30(13):2351-2356.

Memo

Memo:
江西省中医药管理局科技计划（编号：2021B099）
Last Update: 1900-01-01